Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2007 February;142(1) > Giornale Italiano di Dermatologia e Venereologia 2007 February;142(1):29-34

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

THERAPEUTICAL NOTES  


Giornale Italiano di Dermatologia e Venereologia 2007 February;142(1):29-34

language: English

Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis

Ayala Fabrizio, Balato N., Gaudiello F., Ayala Fabio

Department of Dermatology Federico II University, Naples, Italy


PDF  


Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD).
Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL – 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29.
Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event.
Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.

top of page

Publication History

Cite this article as

Corresponding author e-mail